Skip to main content

Riken Omics Center Back After Quake

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Riken Omics Science Center in Yokohama, Japan said today that it has resumed its normal research activities in the wake of the large earthquake that struck off the coast of Tohoku, Japan in early March, causing a massive tsunami that leveled parts of the country's northeast coast.

'[W]e have returned to our normal pace of work and have resume all research activities," Piero Carninci, team leader of the Functional Genomics Technology Team, and leader of the Omics Resource, said. "While we anticipate possible issues stemming from power shortages in mid-summer months, the requirement to cut down on power use has resulted in energy-saving measures which themselves are a positive development."

"The only significant impairment Riken suffered was at our Sendai facility, where there was some damage to the building and to research instruments and equipment," Riken President Noyori Ryoji said in a statement on the institute's website. "Repairs will be required, but we are most grateful that there were no injuries to Riken staff and other personnel."

Ryoji also said that Riken's more immediate concern is about "the considerable damage suffered by a number of universities and research institutions" located in or near Tohoku and Kanto.

Filed under

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.